BioCryst Pharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BCRX research report →
Companywww.biocryst.com
BioCryst Pharmaceuticals, Inc. , a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.
- CEO
- Charles K. Gayer
- IPO
- 1994
- Employees
- 580
- HQ
- Durham, NC, US
Price Chart
Valuation
- Market Cap
- $1.83B
- P/E
- -4.62
- P/S
- 2.07
- P/B
- -3.82
- EV/EBITDA
- -6.72
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 18.89%
- Op Margin
- -43.11%
- Net Margin
- -51.71%
- ROE
- 123.57%
- ROIC
- -121.96%
Growth & Income
- Revenue
- $874.84M · 94.10%
- Net Income
- $263.86M · 396.87%
- EPS
- $1.26 · 393.02%
- Op Income
- $340.99M
- FCF YoY
- 716.08%
Performance & Tape
- 52W High
- $11.31
- 52W Low
- $6.00
- 50D MA
- $9.19
- 200D MA
- $7.91
- Beta
- 0.57
- Avg Volume
- 5.59M
Get TickerSpark's AI analysis on BCRX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 18, 26 | McKee Amy E | sell | 11,180 |
| May 13, 26 | Barnes Alane P | other | 62,500 |
| May 13, 26 | Barnes Alane P | sell | 62,500 |
| May 13, 26 | Barnes Alane P | other | 62,500 |
| Apr 6, 26 | Menon Sandeep | other | 441,350 |
| Apr 6, 26 | Menon Sandeep | other | 205,150 |
| Apr 6, 26 | Menon Sandeep | other | 0 |
| Mar 20, 26 | HEGGIE THERESA | other | 49,933 |
| Mar 20, 26 | HEGGIE THERESA | sell | 49,933 |
| Mar 20, 26 | HEGGIE THERESA | other | 49,933 |
Our BCRX Coverage
We haven't published any research on BCRX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BCRX Report →